-
Funding Type:
Grant Funding
-
Opportunity From:
ASPR BARDA
Important Dates:
Opportunity Description:
The ASPR BARDA has announced up to $500 million in funding for Project NextGen to support Phase 2b clinical trials of novel COVID-19 vaccines that can be administered intranasally or orally. These needle-free vaccines aim to improve vaccine access and ease of administration. The funding will support the following companies:
The awards are among the first to be made through BARDA's Rapid Response Partnership Vehicle and will support the following companies:
- Vaxart of San Francisco will receive up to $453 million for an oral pill vaccine (Ad-5), with an initial $65.7 million for early milestones. Vaxart will conduct its own Phase 2b trial.
- Castlevax, part of the Mount Sinai Health System in New York City, will receive approximately $34 million for an intranasal vaccine (CVAX-01).
- Cyanvac of Athens, Georgia, will receive approximately $40 million for an intranasal vaccine (CVXGA).
The trials for Castlevax and Cyanvac will be conducted in partnership with BARDA’s Clinical Studies Network. These awards follow over $25 million awarded in May for decentralized clinical trial solutions and improved data collection for COVID-19 vaccines. This initiative is part of BARDA’s Project NextGen medical countermeasures portfolio. Visit the Project NextGen portfolio page to learn more.